IL301842A - Methods and compositions for synergistic uptake and retention of small molecule ligands - Google Patents

Methods and compositions for synergistic uptake and retention of small molecule ligands

Info

Publication number
IL301842A
IL301842A IL301842A IL30184223A IL301842A IL 301842 A IL301842 A IL 301842A IL 301842 A IL301842 A IL 301842A IL 30184223 A IL30184223 A IL 30184223A IL 301842 A IL301842 A IL 301842A
Authority
IL
Israel
Prior art keywords
cancer
psma
targeting
agent
agents
Prior art date
Application number
IL301842A
Other languages
English (en)
Hebrew (he)
Inventor
H Bander Neil
Original Assignee
Univ Cornell
H Bander Neil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell, H Bander Neil filed Critical Univ Cornell
Publication of IL301842A publication Critical patent/IL301842A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
IL301842A 2020-10-01 2021-09-28 Methods and compositions for synergistic uptake and retention of small molecule ligands IL301842A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086216P 2020-10-01 2020-10-01
PCT/US2021/052271 WO2022072293A2 (en) 2020-10-01 2021-09-28 Methods and compositions for synergistic uptake and retention of small molecule ligands

Publications (1)

Publication Number Publication Date
IL301842A true IL301842A (en) 2023-06-01

Family

ID=80950778

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301842A IL301842A (en) 2020-10-01 2021-09-28 Methods and compositions for synergistic uptake and retention of small molecule ligands

Country Status (7)

Country Link
US (1) US20240000979A1 (https=)
EP (1) EP4221764A4 (https=)
JP (1) JP2023547999A (https=)
AU (1) AU2021352378A1 (https=)
CA (1) CA3194600A1 (https=)
IL (1) IL301842A (https=)
WO (1) WO2022072293A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
US20240000979A1 (en) * 2020-10-01 2024-01-04 Cornell University Methods and compositions for synergistic uptake and retention of small molecule ligands
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2025029946A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044616A2 (en) * 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
WO2018204477A1 (en) * 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
US20240000979A1 (en) * 2020-10-01 2024-01-04 Cornell University Methods and compositions for synergistic uptake and retention of small molecule ligands

Also Published As

Publication number Publication date
WO2022072293A3 (en) 2022-07-21
EP4221764A4 (en) 2025-12-24
AU2021352378A9 (en) 2024-10-24
WO2022072293A2 (en) 2022-04-07
JP2023547999A (ja) 2023-11-15
US20240000979A1 (en) 2024-01-04
EP4221764A2 (en) 2023-08-09
AU2021352378A1 (en) 2023-06-08
CA3194600A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
US12285503B2 (en) Methods and reagents for tumor targeting with greater efficacy and less toxicity
IL301842A (en) Methods and compositions for synergistic uptake and retention of small molecule ligands
KR100695383B1 (ko) 암을 치료하기 위한 도세탁셀과 ｒｈｕＭＡｂ ＨＥＲ２의조합제제
IL301840A (en) Methods and compositions for increasing the absorption, internalization and/or retention of small molecule ligands
KR20130140033A (ko) 암을 치료하는 방법들
AU2026201845A1 (en) Methods of treating cancer
TWI605815B (zh) 用於製備包含阿米福丁與胺基酸之腎保護劑的組成物及方法
CA2709027A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
AU2021266721A1 (en) Methods for treating pancreatic cancer and other solid tumors
TW202322855A (zh) 人類表皮生長因子第二型受體疫苗組成物以及套組
TW202513554A (zh) 用於治療前列腺癌之組合療法
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
KR20130108583A (ko) 암 치료 또는 암 완화 케어용 옥트레오티드 수식 나노 제제
CN112168971A (zh) 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用